Robert A Herrera

Mr. Robert A Herrera

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Radiotherapy and Oncology
Verified
Journal Article
Open access
KMKathryn E Mittauer
Kathryn E Mittauer
Sreenija YarlagaddaSreenija Yarlagadda
Sreenija Yarlagadda
JBJohn Michael Bryant
John Michael Bryant
NBNema Bassiri
Nema Bassiri
TRTino Romaguera
Tino Romaguera
Michael D. ChuongMichael D. Chuong
Michael D. Chuong
Planning on a static dataset that reflects the simulation day anatomy is routine for SBRT. We hypothesize the quality of on-table adaptive plans is similar to the baseline plan when delivering stereotactic MR-guided adaptive radiotherapy (SMART) for pancreatic cancer (PCa). Sixty-seven inoperable PCa patients were prescribed 50 Gy/5-fraction SMART. Baseline planning included: 3-5 mm gastrointestinal (GI) PRV, 50 Gy optimization target (PTVopt) based on GI PRV, conformality rings, and contracted GTV to guide the hotspot. For each adaptation, GI anatomy was re-contoured, followed by re-optimization. Plan quality was evaluated for target coverage (TC = PTVopt V100%/volume), PTV D90% and D80%, homogeneity index (HI = PTVopt D2%/D98%), prescription isodose/target volume (PITV), low-dose conformity (D2cm = maximum dose at 2 cm from PTVopt/Rx dose), and gradient index (R50%=50% Rx isodose volume/PTVopt volume).A novel global planning metric, termed the Pancreas Adaptive Radiotherapy Score (PARTS), was developed and implemented based on GI OAR sparing, PTV/GTV coverage, and conformality. Adaptive robustness (baseline to fraction 1) and stability (difference between two fractions with highest GI PRV variation) were quantified. OAR constraints were met on all baseline (n = 67) and adaptive (n = 318) plans. Coverage for baseline/adaptive plans was mean ± SD at 44.9 ± 5.8 Gy/44.3 ± 5.5 Gy (PTV D80%), 50.1 ± 4.2 Gy/49.1 ± 4.7 Gy (PTVopt D80%), and 80%±18%/74%±18% (TC), respectively. Mean homogeneity and conformality for baseline/adaptive plans were 0.87 ± 0.25/0.81 ± 0.30 (PITV), 3.81 ± 1.87/3.87 ± 2.0 (R50%), 1.53 ± 0.23/1.55 ± 0.23 (HI), and 58%±7%/59%±7% (D2cm), respectively. PARTS was found to be a sensitive metric due to its additive influence of geometry changes on PARTS' sub-metrics. There were no statistical differences (p > 0.05) for stability, except for PARTS (p = 0.04, median difference -0.6%). Statistical differences for robustness when significant were small for most metrics (<2.0% median). Median adaptive re-optimizations were 2. We describe a 5-fraction ablative SMART planning approach for PCa that is robust and stable during on-table adaption, due to gradients controlled by a GI PRV technique and the use of rings. These findings are noteworthy given that daily interfraction anatomic GI OAR differences are routine, thus necessitating on-table adaptation. This work supports feasibility towards utilizing a patient-independent, template on-table adaptive approach.

7 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Michael D. ChuongMichael D. Chuong
Michael D. Chuong
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
RHRobert A Herrera
Robert A Herrera
MZMelissa Zinovoy
Melissa Zinovoy
KMKathryn E. Mittauer
Kathryn E. Mittauer
MRMarsha Reyngold
Marsha Reyngold
Background: Radiation dose escalation for locally advanced pancreatic cancer (LAPC) using stereotactic magnetic resonance (MR)-guided online adaptive radiation therapy (SMART) or computed tomography (CT)-guided moderately hypofractionated ablative radiation therapy (HART) can achieve favorable outcomes although have not previously been compared. Methods: We performed a multi-center retrospective analysis of SMART (50 Gy/5 fractions) vs. HART (75 Gy/25 fractions or 67.5 Gy/15 fractions with concurrent capecitabine) for LAPC. Gray’s test and Cox proportional regression analyses were performed to identify factors associated with local failure (LF) and overall survival (OS). Results: A total of 211 patients (SMART, n = 91; HART, n = 120) were evaluated, and none had surgery. Median follow-up after SMART and HART was 27.0 and 40.0 months, respectively (p < 0.0002). SMART achieved higher gross tumor volume (GTV) coverage and greater hotspots. Two-year LF after SMART and HART was 6.5% and 32.9% (p < 0.001), while two-year OS was 31.0% vs. 35.3% (p = 0.056), respectively. LF was associated with SMART vs. HART (HR 5.389, 95% CI: 1.298–21.975; p = 0.021) and induction mFOLFIRINOX vs. non-mFOLFIRINOX (HR 2.067, 95% CI 1.038–4.052; p = 0.047), while OS was associated with CA19-9 decrease > 40% (HR 0.725, 95% CI 0.515–0.996; p = 0.046) and GTV V120% (HR 1.022, 95% CI 1.006–1.037; p = 0.015). Acute grade > 3 toxicity was similar (3.3% vs. 5.8%; p = 0.390), while late grade > 3 toxicity was less common after SMART (2.2% vs. 9.2%; p = 0.037). Conclusions: Ablative SMART and HART both achieve favorable oncologic outcomes for LAPC with minimal toxicity. We did not observe an OS difference, although technical advantages of SMART might improve target coverage and reduce LF.

10 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RHRobert A Herrera
Robert A Herrera
EAEYUB YASAR AKDEMIR
EYUB YASAR AKDEMIR
RKRupesh Kotecha
Rupesh Kotecha
KMKathryn E. Mittauer
Kathryn E. Mittauer
MHMatthew david Hall
Matthew david Hall
Michael D. ChuongMichael D. Chuong
Michael D. Chuong
Background/Objectives: Over the past decade, significant advances have been made in image-guided radiotherapy (RT) particularly with the introduction of magnetic resonance (MR)-guided radiotherapy (MRgRT). However, the optimal clinical applications of MRgRT are still evolving. The intent of this analysis was to describe our institutional MRgRT utilization patterns and evolution therein, specifically as an early adopter within a center endowed with multiple other technology platforms. Materials/Methods: We retrospectively evaluated patterns of MRgRT utilization for patients treated with a 0.35-Tesla MR-Linac at our institution from April 2018 to April 2024. We analyzed changes in utilization across six annualized periods: Period 1 (April 2018–April 2019) through Period 6 (April 2023–April 2024). We defined ultra-hypofractionation (UHfx) as 5 or fewer fractions with a minimum fractional dose of 5 Gy. Electronic health records were reviewed, and data were extracted related to patient, tumor, and treatment characteristics. Results: A total of 823 treatment courses were delivered to 712 patients treated for 854 lesions. The most commonly treated sites were the pancreas (242 [29.4%]), thorax (172; 20.9%), abdominopelvic lymph nodes (107; 13.0%), liver (72; 8.7%), and adrenal glands (68; 8.3%). The median total prescribed dose of 50 Gy in five fractions (fxs) was typically delivered in consecutive days with automatic beam gating in inspiration breath hold. The median biologically effective dose (α/β = 10, BED10) was 94.4 Gy with nearly half (404, 49.1%) of all courses at a prescribed BED10 ≥ 100 Gy, which is widely regarded as a highly effective ablative dose. Courses in Period 6 vs. Period 1 more often had a prescribed BED10 ≥ 100 Gy (60.2% vs. 41.6%; p = 0.004). Of the 6036 total delivered fxs, nearly half (2643, 43.8%) required at least one fx of on-table adaptive radiotherapy (oART), most commonly for pancreatic tumors (1081, 17.9%). UHfx was used in over three quarters of all courses (630, 76.5%) with 472 (57.4%) of these requiring oART for at least one fraction. The relative utilization of oART increased significantly from Period 1 to Period 6 (37.6% to 85.0%; p < 0.001); a similar increase in the use of UHfx (66.3% to 89.5%; p < 0.001) was also observed. The median total in-room time for oART decreased from 81 min in Period 1 to 45 min in Period 6, while for non-oART, it remained stable around 40 min across all periods. Conclusions: Our institution implemented MRgRT with a priority for targeting mobile extracranial tumors in challenging anatomic locations that are frequently treated with dose escalation, require enhanced soft-tissue visualization, and could benefit from an ablative radiotherapy approach. Over the period under evaluation, the use of high-dose ablative doses (BED10 ≥ 100 Gy), oART and UHfx (including single-fraction ablation) increased significantly, underscoring both a swift learning curve and ability to optimize processes to maximize throughput and efficiency.

20 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AKAdeel Kaiser
Adeel Kaiser
NLNicole Luther
Nicole Luther
KMKathryn E. Mittauer
Kathryn E. Mittauer
AGAmna Gul
Amna Gul
RHRobert A Herrera
Robert A Herrera
Michael D. ChuongMichael D. Chuong
Michael D. Chuong
Background/Objectives: Non-ablative stereotactic body radiation therapy (SBRT) is commonly employed for locally advanced pancreatic cancer (LAPC) using computed tomography-guided radiotherapy (CTgRT) without online adaptive radiation therapy (oART). The safe delivery of ablative SBRT has been demonstrated using stereotactic magnetic resonance-guided online adaptive radiation therapy (SMART). We performed an in silico comparison of non-adapted CTgRT versus SMART to better understand the potential benefit of oART for ablative pancreatic SBRT. Methods: We retrospectively evaluated original and daily adapted SMART plans that were previously delivered for 20 consecutive LAPC cases (120 total plans across all patients) treated on a 0.35 T MR-linac prescribed to 50 Gy (gross disease) and 33 Gy (elective sites) simultaneously in five fractions. Six comparative CTgRT plans for each patient (one original, five daily treatment) were retrospectively generated with the same prescribed dose and planning parameters as the SMART plans assuming no oART availability. The impact of daily anatomic changes on CTgRT and SMART plans without oART was evaluated across each treatment day MRI scan acquired for SMART. Results: Ninety percent of cases involved the pancreatic head. No statistically significant differences were seen between CTgRT and SMART with respect to target coverage. Nearly all (96%) fractions planned on either CT or MRI platforms exceeded at least one GI organ at risk (OAR) constraint without oART. Significant differences favoring SMART over non-adaptive CTgRT were observed for the duodenum V35 Gy ≤ 0.5 cc (34.2 vs. 41.9 Gy, p = 0.0035) and duodenum V40 Gy ≤ 0.03 cc (37 vs. 52.5 Gy, p = 0.0006) constraints. Stomach V40 Gy trended towards significance favoring SMART (37 vs. 40.3 Gy, p = 0.057) while no significant differences were seen. Conclusions: This is the first study that quantifies the frequency and extent of GI OAR constraint violations that would occur during ablative five-fraction SBRT using SMART vs. CTgRT. GI OAR constraint violations are expected for most fractions without oART whereas all constraints can be achieved with oART. As such, these data suggest that oART should be required for ablative five-fraction pancreatic SBRT.

5 January 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
MMMatthew Mills
Matthew Mills
RKRupesh Kotecha
Rupesh Kotecha
RHRobert A Herrera
Robert A Herrera
TKTugce Kutuk
Tugce Kutuk
MFMatthew Fahey
Matthew Fahey
SRStephen A. Rosenberg
Stephen A. Rosenberg
Purpose: While dose escalation is associated with improved local control (LC) for adrenal gland metastases (AGMs), the proximity of gastrointestinal (GI) organs-at-risk (OARs) limits the dose that can be safely prescribed via CT-based stereotactic body radiation therapy (SBRT). The advantages of magnetic resonance-guided SBRT (MRgSBRT), including tumor tracking and online plan adaptation, facilitate safe dose escalation. Methods: This is a multi-institutional review of 57 consecutive patients who received MRgSBRT on a 0.35-T MR linac to 61 AGMs from 2019 to 2021. The Kaplan-Meier method was used to estimate overall survival (OS), progression-free survival (PFS), and LC, and the Cox proportional hazards model was utilized for univariate analysis (UVA). Results: Median follow up from MRgSBRT was 16.4 months (range [R]: 1.1-39 months). Median age was 67 years (R: 28-84 years). Primary histologies included non-small cell lung cancer (N = 38), renal cell carcinoma (N = 6), and melanoma (N = 5), amongst others. The median maximum diameter was 2.7 cm (R: 0.6-7.6 cm), and most AGMs were left-sided (N = 32). The median dose was 50 Gy (R: 30-60 Gy) in 5-10 fractions with a median BED10 of 100 Gy (R: 48-132 Gy). 45 cases (74 %) required adaptation for at least 1 fraction (median: 4 fractions, R: 0-10). Left-sided AGMs required adaptation in at least 1 fraction more frequently than right-sided AGMs (88 % vs 59 %, p = 0.018). There were 3 cases of reirradiation, including 60 Gy in 10 fractions (N = 1) and 40 Gy in 5 fractions (N = 2). One-year LC, PFS, and OS were 92 %, 52 %, and 78 %, respectively. On UVA, melanoma histology predicted for inferior 1-year LC (80 % vs 93 %, p = 0.012). There were no instances of grade 3+ toxicity. Conclusions: We demonstrate that MRgSBRT achieves favorable early LC and no grade 3 + toxicity despite prescribing a median BED10 of 100 Gy to targets near GI OARs.

31 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RHRobert A Herrera
Robert A Herrera
SUSirikorn Unsri
Sirikorn Unsri
KMKathryn E. Mittauer
Kathryn E. Mittauer
RKRupesh Kotecha
Rupesh Kotecha
AKAdeel Kaiser
Adeel Kaiser
Michael D. ChuongMichael D. Chuong
Michael D. Chuong
Purpose: While magnetic resonance-guided radiation therapy (MRgRT) may provide significant clinical advantages, delivery times tend to be longer than other radiation therapy (RT) modalities and published data on these times are limited. We evaluated longitudinal treatment times across our 8-year institutional MRgRT experience. Methods/Materials: A retrospective analysis of patients treated at our institution on a 0.35-Tesla MR-Linac between April 2018 and April 2026 was performed. All fractions were delivered with continuous intrafraction cine-MRI, soft tissue tracking, automatic beam gating, and online adaptive radiation therapy (oART) when indicated. The primary objective was to characterize changes in total in-room time (TIRT), treatment delivery time (TDT), and total adaptive time (TAT). For analysis of efficiency gains, our overall experience was separated into early (2018–2022) and late (2022–2026) periods. Results: A total of 1026 patients, 1203 treatment courses, and 7665 fractions were included. The median age was 69 years (range: 19–94) and the most commonly treated sites by treatment course were pancreas (n = 430; 35.7%), thorax (n = 203; 16.9%), abdominopelvic lymph nodes (n = 181; 15.0%), liver (n = 138; 11.5%), and adrenal gland (n = 83; 6.9%). The median prescription dose was 50 Gy (range: 16.0–76.0) in a median of five fractions (range: 1–36). Breath-hold and stereotactic body radiation therapy (SBRT) were used in 87.9% and 88.5% of treatment courses, respectively. From the early (2018–2022) to late (2022–2026) study period, the proportion of fractions utilizing SBRT (49.9% vs. 81.1%; p < 0.001), oART (32.9% vs. 80.2%; p < 0.001), respiratory gating (75.9% vs. 88.8%; p < 0.001), and elective nodal coverage (61.8% vs. 78.2%; p < 0.001) increased, as did the proportion of pancreatic treatments (20.4% vs. 38.4%; p < 0.001) and the utilization of single-fraction courses (3.4% vs. 10.3%; p < 0.001). Despite this increasing complexity between study periods, median oART TIRT decreased from 67.0 to 48.0 min (28.4% reduction; p < 0.001), driven primarily by a reduction in TAT from 20.0 to 7.0 min, p < 0.001. Pancreatic oART fractions showed the greatest improvement (median TIRT, 70.0 to 47.0 min; p < 0.001). In 2022–2026, 78.1% of oART fractions were completed within 60 min vs. 35.5% in 2018–2022 (p < 0.001). Conclusions: Ablative MRgRT, with or without oART, can often be delivered in 60 min or less, including for mobile and anatomically unfavorable tumors. Future software and hardware advances are expected to further improve MRgRT treatment efficiency.